Macrophages as a Cell-Based Therapy for Liver Disease
Open accessAbstract
Liver failure arising from acute and chronic liver disease is an unmet clinical need that urgently requires novel therapeutic options in addition to orthotopic liver transplantation. Cell therapies offer new strategies to recover liver function through the reconstitution of healthy parenchyma and resolution of tissue pathology. Macrophages are professional phagocytes that comprise a key part of the innate immune system providing an important defense mechanism against invading pathogens. Macrophages are an inherently diverse cell type with respect to ontogeny, tissue distribution, phenotype, and function. The ability of macrophages to afford innate immunity, efficiently scavenge apoptotic/necrotic cells, and modulate local tissue microenvironment makes them an attractive cell therapy candidate for various diseases. This review aims to outline the rationale and utility of macrophages to serve as a potential cell therapy for liver disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Safety concerns remain because transplanted macrophages risk acquiring a potentially deleterious phenotype due to microenvironmental cues.
“Nevertheless, safety concerns remain, as transplanted macrophages risk acquiring a potentially deleterious phenotype due to microenvironmental cues [40].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [40]
Macrophages are a highly plastic and versatile cell type, exhibiting the capacity to adopt a broad spectrum of phenotypes in response to stimuli in the surrounding microenvironment.
“Macrophages are a highly plastic and versatile cell type, exhibiting the capacity to adopt a broad spectrum of phenotypes in response to stimuli in the surrounding microenvironment [40].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [40]
The citation lists haven’t been fetched yet
References 126 · Cited by 36
- Authors
- Starkey Lewis, P. J., Moroni, F., & Forbes, S. J.
- Affiliations
- MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom
- MRC Centre for Regenerative Medicine (GB)
- Corresponding author
- Forbes, Stuart J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2019-06-26
- Volume
- 39
- Issue
- 04
- Pages
- 442-451
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2955029407
- Cited by
- 36
- References
- 126
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 1
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- macrophages, cell therapy, liver disease, liver failure, innate immunity, macrophage heterogeneity, tissue microenvironment, phagocytosis
- MeSH terms
- Humans, Immunity, Innate, Liver Diseases, Macrophages, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
